Table 1 the primary characteristics of the eligible studies in more detail
Study Year | Country | Study period | Age | N | Interventions | ||
|---|---|---|---|---|---|---|---|
morphine | oxycodone; | morphine | oxycodone; | ||||
Nashat Y 2003 | USA | NR | NR | NR | 20 | 22 | over-encapsulated oxymorphone ER (10, 20, or 40Â mg) or over- encapsulated oxycodone CR (20, 40, or 80Â mg). |
Satoshi Inoue 2017 | Japan | 2014–2015 | 70.1 | 68.4 | 86 | 92 | hydromorphone extended-release tablets plus placebo oxycodone hydrochloride extended-release tablets 4 mg/day or placebo hydromorphone extended-release tablets plus oxycodone hydrochloride extended-release tablets 10 mg/day orally for 7 days (once-daily dosing for hydromorphone and twice-daily dosing for oxycodone) |
O. Corli 2016 | Italy | 2011.5–2014.7 | 67.5 | 66.9 | 122 | 125 | morphine or oxycodone for 28 days.The initial dose of opioid was based on the recommendations of the European Association for Palliative Care/EAPC |
Julia Riley 2015 | UK | 2006.5–2011.7 | 59.2 | 58.9 | 100 | 100 | the starting dose was determined by the treating physician on an individual patient basis and titrated accordingly until adequate pain control was achieved or intolerable side effects were re- ported by the patient. |
Shiying Yu 2014 | China | NR | 53.5 | 52.7 | 125 | 123 | require between 40 and 184Â mg of oral morphine or morphine equivalents every 24Â h for chronic management of cancer pain |
S. Mercadante 2010 | Italy | NR | NR | NR | 21 | 25 | receive 30Â mg/d of sustained release oralmorphine or sustained release oral oxycodone(20Â mg/d). |
Ernesto Zecca 2016 | Italy | 2006.9.14–2007.12.21 | 61.8 | 62.1 | 95 | 92 | Opioid dosages were reported as oral morphine equivalent daily dose (MEDD) mg, converted using a 1.5:1 ratio between morphine and oxycodone. |